We are glad to announce that NeuroSolve’s Clinical Trial has been successfully registered on Pan African Clinical Trial Registry – PACTR. This important achievement is only the beginning of our fight against Neurocysticercosis. This Neglected Tropical Disease caused by Taenia solium is a major cause of acquired epilepsy in middle-and-low-income countries. NeuroSolve is a four-year project funded by EDCTP3, and started on May 1, 2023. The African-European research consortium involves the University of Dar es Salaam (UDSM – Tanzania), Sokoine University of Agriculture (SUA – Tanzania), University of Zambia (UNZA – Zambia), Revolution Worldwide Srl – Impresa Sociale (R-EvoWW – Italy) and Universiteit Ghent (UGent – Belgium). NeuroSolve is committed to fight taeniasis/Neurocysticercosis (NCC) disease in Sub-Saharan Africa.
